

# Boccardi Marina

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/834920/boccardi-marina-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

101  
papers

4,185  
citations

35  
h-index

62  
g-index

114  
ext. papers

5,140  
ext. citations

5  
avg. IF

4.85  
L-index

#	Paper	IF	Citations
101	Answer to "Social cognition assessment for mild neurocognitive disorders".. <i>Alzheimerts and Dementia</i> , <b>2022</b> ,	1.2	0
100	2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2021</b> , 48, 2121-2139	8.8	18
99	The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2021</b> , 48, 2140-2156	8.8	31
98	Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2021</b> , 48, 2086-2096	8.8	4
97	The strategic biomarker roadmap for the validation of Alzheimer's diagnostic biomarkers: methodological update. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2021</b> , 48, 2070-2085	8.8	10
96	Harmonizing neuropsychological assessment for mild neurocognitive disorders in Europe. <i>Alzheimerts and Dementia</i> , <b>2021</b> ,	1.2	6
95	Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2021</b> , 48, 2200-2211	8.8	4
94	Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2021</b> , 48, 2110-2120	8.8	9
93	Clinical validity of increased cortical uptake of [F]flortaucipir on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase biomarker development framework. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2021</b> , 48, 2097-2109	8.8	14
92	Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2021</b> , 48, 2157-2168	8.8	5
91	Distance assessment of cognitive deficits in older immigrants.. <i>Alzheimerts and Dementia</i> , <b>2021</b> , 17 Suppl 8, e049315	1.2	
90	The biomarker roadmap for the validation for Alzheimer's biomarkers: Methodological update for biomarkers of tauopathy. <i>Alzheimerts and Dementia</i> , <b>2020</b> , 16, e039063	1.2	2
89	Comparison of visual criteria for amyloid-PET reading: could criteria merging reduce inter-rater variability?. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2020</b> , 64, 414-421	1.4	3
88	Italian consensus recommendations for a biomarker-based aetiological diagnosis in mild cognitive impairment patients. <i>European Journal of Neurology</i> , <b>2020</b> , 27, 475-483	6	13
87	The A/T/N model applied through imaging biomarkers in a memory clinic. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2020</b> , 47, 247-255	8.8	9
86	Incremental value of amyloid-PET versus CSF in the diagnosis of Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2020</b> , 47, 270-280	8.8	17
85	Medial temporal lobe atrophy and posterior atrophy scales normative values. <i>NeuroImage: Clinical</i> , <b>2019</b> , 24, 101936	5.3	8

84	Progress update from the hippocampal subfields group. <i>Alzheimerts and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2019</b> , 11, 439-449	5.2	16
83	Assessment of longitudinal hippocampal atrophy in the first year after ischemic stroke using automatic segmentation techniques. <i>NeuroImage: Clinical</i> , <b>2019</b> , 24, 102008	5.3	12
82	Abnormalities in functional connectivity in borderline personality disorder: Correlations with metacognition and emotion dysregulation. <i>Psychiatry Research - Neuroimaging</i> , <b>2019</b> , 283, 118-124	2.9	21
81	A comparison of automated segmentation and manual tracing in estimating hippocampal volume in ischemic stroke and healthy control participants. <i>NeuroImage: Clinical</i> , <b>2019</b> , 21, 101581	5.3	19
80	AMYPAD Diagnostic and Patient Management Study: Rationale and design. <i>Alzheimerts and Dementia</i> , <b>2019</b> , 15, 388-399	1.2	19
79	Quantitative appraisal of the Amyloid Imaging Taskforce appropriate use criteria for amyloid-PET. <i>Alzheimerts and Dementia</i> , <b>2018</b> , 14, 1088-1098	1.2	10
78	Automated assessment of FDG-PET for differential diagnosis in patients with neurodegenerative disorders. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2018</b> , 45, 1557-1566	8.8	24
77	Assessing FDG-PET diagnostic accuracy studies to develop recommendations for clinical use in dementia. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2018</b> , 45, 1470-1486	8.8	15
76	Clinical utility of FDG-PET in amyotrophic lateral sclerosis and Huntington's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2018</b> , 45, 1546-1556	8.8	17
75	Clinical utility of FDG-PET for the clinical diagnosis in MCI. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2018</b> , 45, 1497-1508	8.8	38
74	European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain F-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus. <i>European Journal of Neurology</i> , <b>2018</b> , 25, 1201-1217	6	92
73	Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementia. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2018</b> , 45, 1509-1525	8.8	55
72	Diagnostic utility of FDG-PET in the differential diagnosis between different forms of primary progressive aphasia. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2018</b> , 45, 1526-1533	8.8	23
71	P4-064: THE EFFECT OF APOE ON WHITE MATTER LESIONS <b>2018</b> , 14, P1457-P1457		
70	IC-P-071: THE EFFECT OF APOE ON WHITE MATTER LESIONS <b>2018</b> , 14, P63-P64		1
69	Clinical utility of FDG PET in Parkinson's disease and atypical parkinsonism associated with dementia. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2018</b> , 45, 1534-1545	8.8	60
68	Diagnostic utility of 18F-Fluorodeoxyglucose positron emission tomography (FDG-PET) in asymptomatic subjects at increased risk for Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2018</b> , 45, 1487-1496	8.8	22
67	Reference standard space hippocampus labels according to the European Alzheimer's Disease Consortium-Alzheimer's Disease Neuroimaging Initiative harmonized protocol: Utility in automated volumetry. <i>Alzheimerts and Dementia</i> , <b>2017</b> , 13, 893-902	1.2	21

66	Clinical validity of medial temporal atrophy as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. <i>Neurobiology of Aging</i> , <b>2017</b> , 52, 167-182.e1	5.6	51
65	The biomarker-based diagnosis of Alzheimer's disease. 1-ethical and societal issues. <i>Neurobiology of Aging</i> , <b>2017</b> , 52, 132-140	5.6	26
64	Biomarkers for the diagnosis of Alzheimer's disease in clinical practice: an Italian intersocietal roadmap. <i>Neurobiology of Aging</i> , <b>2017</b> , 52, 119-131	5.6	21
63	Clinical validity of delayed recall tests as a gateway biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. <i>Neurobiology of Aging</i> , <b>2017</b> , 52, 153-166	5.6	38
62	Clinical validity of cerebrospinal fluid A $\beta$ 2, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. <i>Neurobiology of Aging</i> , <b>2017</b> , 52, 196-213	5.6	73
61	Clinical validity of brain fluorodeoxyglucose positron emission tomography as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. <i>Neurobiology of Aging</i> , <b>2017</b> , 52, 183-195	5.6	67
60	Clinical validity of presynaptic dopaminergic imaging with $^{18}$ F-ioflupane and noradrenergic imaging with I-MIBG in the differential diagnosis between Alzheimer's disease and dementia with Lewy bodies in the context of a structured 5-phase development framework. <i>Neurobiology of Aging</i> , <b>2017</b> , 52, 228-242	5.6	26
59	Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. <i>Neurobiology of Aging</i> , <b>2017</b> , 52, 214-227	5.6	52
58	The biomarker-based diagnosis of Alzheimer's disease. 2-lessons from oncology. <i>Neurobiology of Aging</i> , <b>2017</b> , 52, 141-152	5.6	33
57	Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. <i>Lancet Neurology, The</i> , <b>2017</b> , 16, 661-676	24.1	308
56	A harmonized segmentation protocol for hippocampal and parahippocampal subregions: Why do we need one and what are the key goals?. <i>Hippocampus</i> , <b>2017</b> , 27, 3-11	3.5	84
55	Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly. <i>Neurobiology of Aging</i> , <b>2017</b> , 49, 60-68	5.6	500
54	Assessment of the Incremental Diagnostic Value of Florbetapir F 18 Imaging in Patients With Cognitive Impairment: The Incremental Diagnostic Value of Amyloid PET With [ $^{18}$ F]-Florbetapir (INDIA-FBP) Study. <i>JAMA Neurology</i> , <b>2016</b> , 73, 1417-1424	17.2	65
53	Do Beliefs about the Pathogenetic Role of Amyloid Affect the Interpretation of Amyloid PET in the Clinic. <i>Neurodegenerative Diseases</i> , <b>2016</b> , 16, 111-7	2.3	3
52	Automated hippocampal segmentation in 3D MRI using random undersampling with boosting algorithm. <i>Pattern Analysis and Applications</i> , <b>2016</b> , 19, 579-591	2.3	17
51	Integrating longitudinal information in hippocampal volume measurements for the early detection of Alzheimer's disease. <i>NeuroImage</i> , <b>2016</b> , 125, 834-847	7.9	58
50	Quantitative comparison of 21 protocols for labeling hippocampal subfields and parahippocampal subregions in in vivo MRI: towards a harmonized segmentation protocol. <i>NeuroImage</i> , <b>2015</b> , 111, 526-417	7.9	209
49	Training labels for hippocampal segmentation based on the EADC-ADNI harmonized hippocampal protocol. <i>Alzheimers and Dementia</i> , <b>2015</b> , 11, 175-83	1.2	76

48	The EADC-ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: evidence of validity. <i>Alzheimerts and Dementia</i> , <b>2015</b> , 11, 111-25	1.2	137
47	Harmonized benchmark labels of the hippocampus on magnetic resonance: the EADC-ADNI project. <i>Alzheimerts and Dementia</i> , <b>2015</b> , 11, 151-60.e5	1.2	32
46	Manual segmentation qualification platform for the EADC-ADNI harmonized protocol for hippocampal segmentation project. <i>Alzheimerts and Dementia</i> , <b>2015</b> , 11, 161-74	1.2	16
45	Relationship between hippocampal atrophy and neuropathology markers: a 7T MRI validation study of the EADC-ADNI Harmonized Hippocampal Segmentation Protocol. <i>Alzheimerts and Dementia</i> , <b>2015</b> , 11, 139-50	1.2	51
44	Delphi definition of the EADC-ADNI Harmonized Protocol for hippocampal segmentation on magnetic resonance. <i>Alzheimerts and Dementia</i> , <b>2015</b> , 11, 126-38	1.2	96
43	Hippocampal and amygdalar local structural differences in elderly patients with schizophrenia. <i>American Journal of Geriatric Psychiatry</i> , <b>2015</b> , 23, 47-58	6.5	10
42	Operationalizing protocol differences for EADC-ADNI manual hippocampal segmentation. <i>Alzheimerts and Dementia</i> , <b>2015</b> , 11, 184-94	1.2	40
41	Multiple RF classifier for the hippocampus segmentation: Method and validation on EADC-ADNI Harmonized Hippocampal Protocol. <i>Physica Medica</i> , <b>2015</b> , 31, 1085-1091	2.7	12
40	Abnormalities in cortical gray matter density in borderline personality disorder. <i>European Psychiatry</i> , <b>2015</b> , 30, 221-7	6	17
39	Occipital sources of resting-state alpha rhythms are related to local gray matter density in subjects with amnesic mild cognitive impairment and Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2015</b> , 36, 556-70	5.6	68
38	Establishing magnetic resonance images orientation for the EADC-ADNI manual hippocampal segmentation protocol. <i>Journal of Neuroimaging</i> , <b>2014</b> , 24, 509-14	2.8	18
37	Impact of alcohol consumption in healthy adults: a magnetic resonance imaging investigation. <i>Psychiatry Research - Neuroimaging</i> , <b>2014</b> , 224, 96-103	2.9	8
36	Coalition Against Major Diseases/European Medicines Agency biomarker qualification of hippocampal volume for enrichment of clinical trials in predementia stages of Alzheimer's disease. <i>Alzheimerts and Dementia</i> , <b>2014</b> , 10, 421-429.e3	1.2	66
35	IC-P-124: VALIDATION OF THE EADC-ADNI HARMONIZED PROTOCOL FOR MANUAL HIPPOCAMPAL SEGMENTATION <b>2014</b> , 10, P70-P70		2
34	Automated voxel-by-voxel tissue classification for hippocampal segmentation: methods and validation. <i>Physica Medica</i> , <b>2014</b> , 30, 878-87	2.7	27
33	Medial temporal atrophy in early and late-onset Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2014</b> , 35, 2004-12	5.6	46
32	Structural brain features of borderline personality and bipolar disorders. <i>Psychiatry Research - Neuroimaging</i> , <b>2013</b> , 213, 83-91	2.9	37
31	Striatal morphology in early-onset and late-onset Alzheimer's disease: a preliminary study. <i>Neurobiology of Aging</i> , <b>2013</b> , 34, 1728-39	5.6	36

30	Manual segmentation certification platform <b>2013</b> ,		1
29	Atypical nucleus accumbens morphology in psychopathy: another limbic piece in the puzzle. <i>International Journal of Law and Psychiatry</i> , <b>2013</b> , 36, 157-67	2.6	27
28	Volumetric and topographic differences in hippocampal subdivisions in borderline personality and bipolar disorders. <i>Psychiatry Research - Neuroimaging</i> , <b>2012</b> , 203, 132-8	2.9	31
27	Norms for imaging markers of brain reserve. <i>Journal of Alzheimers Disease</i> , <b>2012</b> , 31, 623-33	4.3	12
26	Delphi Consensus on Landmarks for the Manual Segmentation of the Hippocampus on MRI: Preliminary Results from the EADC-ADNI Harmonized Protocol Working Group (S04.003). <i>Neurology</i> , <b>2012</b> , 78, S04.003-S04.003	6.5	3
25	Survey of protocols for the manual segmentation of the hippocampus: preparatory steps towards a joint EADC-ADNI harmonized protocol. <i>Journal of Alzheimers Disease</i> , <b>2011</b> , 26 Suppl 3, 61-75	4.3	111
24	Cortex and amygdala morphology in psychopathy. <i>Psychiatry Research - Neuroimaging</i> , <b>2011</b> , 193, 85-92	2.9	92
23	Hippocampal and amygdalar volume changes in elderly patients with Alzheimer's disease and schizophrenia. <i>Psychiatry Research - Neuroimaging</i> , <b>2011</b> , 192, 77-83	2.9	28
22	Local amygdala structural differences with 3T MRI in patients with Alzheimer disease. <i>Neurology</i> , <b>2011</b> , 76, 727-33	6.5	56
21	Clinical and medial temporal features in a family with mood disorders. <i>Neuroscience Letters</i> , <b>2010</b> , 468, 93-7	3.3	19
20	Abnormal hippocampal shape in offenders with psychopathy. <i>Human Brain Mapping</i> , <b>2010</b> , 31, 438-47	5.9	50
19	The CST3 B haplotype is associated with frontotemporal lobar degeneration. <i>European Journal of Neurology</i> , <b>2010</b> , 17, 143-6	6	11
18	Alexithymia in healthy women: a brain morphology study. <i>Journal of Affective Disorders</i> , <b>2009</b> , 114, 208-15	5.6	75
17	White-matter lesions along the cholinergic tracts are related to cortical sources of EEG rhythms in amnesic mild cognitive impairment. <i>Human Brain Mapping</i> , <b>2009</b> , 30, 1431-43	5.9	55
16	HOXA1 A218G polymorphism is associated with smaller cerebellar volume in healthy humans. <i>Journal of Neuroimaging</i> , <b>2009</b> , 19, 353-8	2.8	11
15	The Italian Brain Normative Archive of structural MR scans: norms for medial temporal atrophy and white matter lesions. <i>Aging Clinical and Experimental Research</i> , <b>2009</b> , 21, 266-76	4.8	28
14	H1 haplotype of the MAPT gene is associated with lower regional gray matter volume in healthy carriers. <i>European Journal of Human Genetics</i> , <b>2009</b> , 17, 287-94	5.3	9
13	Effect of the XbaI polymorphism of estrogen receptor alpha on postmenopausal gray matter. <i>Neuroscience Letters</i> , <b>2008</b> , 434, 304-9	3.3	8

12	Hippocampal shape differences in dementia with Lewy bodies. <i>NeuroImage</i> , <b>2008</b> , 41, 699-705	7.9	43
11	Cognitive rehabilitation for severe dementia: critical observations for better use of existing knowledge. <i>Mechanisms of Ageing and Development</i> , <b>2006</b> , 127, 166-72	5.6	14
10	The effect of apolipoprotein polymorphism on brain in mild cognitive impairment: a voxel-based morphometric study. <i>Dementia and Geriatric Cognitive Disorders</i> , <b>2006</b> , 22, 60-6	2.6	12
9	Effects of estrogens on cognition and brain morphology: involvement of the cerebellum. <i>Maturitas</i> , <b>2006</b> , 54, 222-8	5	35
8	Effects of hormone therapy on brain morphology of healthy postmenopausal women: a Voxel-based morphometry study. <i>Menopause</i> , <b>2006</b> , 13, 584-91	2.5	62
7	Influence of serotonin receptor 2A His452Tyr polymorphism on brain temporal structures: a volumetric MR study. <i>European Journal of Human Genetics</i> , <b>2006</b> , 14, 443-9	5.3	31
6	Topographic correspondence between white matter hyperintensities and brain atrophy. <i>Journal of Neurology</i> , <b>2006</b> , 253, 919-27	5.5	26
5	Frontotemporal dementia as a neural system disease. <i>Neurobiology of Aging</i> , <b>2005</b> , 26, 37-44	5.6	116
4	APOE and modulation of Alzheimer's and frontotemporal dementia. <i>Neuroscience Letters</i> , <b>2004</b> , 356, 167-70	3.3	32
3	The MRI pattern of frontal and temporal brain atrophy in fronto-temporal dementia. <i>Neurobiology of Aging</i> , <b>2003</b> , 24, 95-103	5.6	94
2	Clinical characteristics of frontotemporal patients with symmetric brain atrophy. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , <b>2002</b> , 252, 235-9	5.1	9
1	Amygdaloid atrophy in frontotemporal dementia and Alzheimer's disease. <i>Neuroscience Letters</i> , <b>2002</b> , 335, 139-43	3.3	31